› $150,000,000 verdict in personal injury case
One year ago this month, the Food and Drug Administration (FDA) issued a black box warning on a common type of laxative known as oral sodium phosphate, or OSP, available both over-the-counter and by prescription. After years of investigation, the FDA finally alerted health care providers and the public of the risk of a serious kidney injury known as acute phosphate nephropathy associated with the use of OSPs.
Attorney Russell Todd Abney with Beasley Allen Law Firm has filed a lawsuit against C.B. Fleet Company, Inc., on behalf of Mary Little, a resident of Newton County, Georgia, claiming that the plaintiff suffered severe personal injuries as a result of ingesting Fleet’s over-the-counter product known as Fleet Phospho-soda.
Laxatives, like Fleet Phospho-Soda, an oral sodium phosphate (OSP) product, have been sold over the counter for more than a century, so it may come as some surprise that these products suddenly fall under a Food and Drug Administration (FDA) warning that links the use of OSPs to a serious kidney injury.
Some people who suffer from kidney problems may not realize their condition may be linked to products used to cleanse the bowel before medical procedures like colonoscopies, says Ben Locklar, shareholder with Beasley Allen Law Firm. It wasn’t until around 2005 that doctors began making the connection between oral sodium phosphate (OSP) products and a serious kidney injury known as acute phosphate nephropathy. Since then, more and more cases have been reported and hundreds of lawsuits have ensued.
